Perspectives from the ICU


Melissa discusses CRRT use on patient with life-threatening arrythmia

"I just remember he was suffering from a life-threatening arrhythmia, attributed to the potassium levels. And he was too unstable for normal dialysis. Because we had that option (CRRT), we were able to decrease his serum potassium rapidly, without worsening his hypotension, without worsening his other organ failure, and stop the arrhythmogenic situation."

– Melissa Bastin-Thompson, PharmD, BCPS

Becca talks about using CRRT on a cardiac-arrest patient

"We had a cardiac arrest patient who was still not talkative after hypothermic protocol. We did CRRT on him just to see if it would help. I came in on Monday and he’s talking and making jokes. And I mean it was just amazing…"

– Becca Bauer, RN

Dr. Aycinena discusses his experience with CRRT for patient with mantle cell lymphoma

"The most dramatic cases that I have experienced both had mantle cell lymphoma. I remember one patient came in loaded on pressors…we thought was going to pass away and he did a one-eighty, and within 24 hours was off any pressors. I think the (CRRT) combined with the chemotherapy really made a difference."

– Juan Carlos Aycinena, MD

Jillian discusses use of CRRT on patient with HUS

"We had a young girl come in that ended up having HUS. And she was literally on her deathbed. We hooked her up (to CRRT) and three days later she was extubated, a week and a half later she was out of the ICU, and two weeks later back at school."

– Jillian Kouns, RN

Clinical Questions

Do you find the PRISMAFLEX System easy to use when delivering CRRT?

How does Baxter’s CRRT Program help provide value to your hospital?

How has Baxter’s Complete Support made a difference for your CRRT program?

What are the keys to success with implementing a CRRT program?

What factors potentially affect patient safety when delivering CRRT?

How do you avoid treatment downtime?

How does the Flexibility of the PRISMAFLEX System help you on a daily basis?

The PRISMAFLEX and PRISMAX Systems are intended for:
Continuous Renal Replacement Therapy (CRRT) for patients weighing 20 kilograms or more with acute renal failure and/or fluid overload.

Therapeutic Plasma Exchange (TPE) therapy for patients weighing 20 kilograms or more with diseases where fluid removal of plasma components is indicated.

Rx Only. For safe and proper use of products mentioned herein refer to the appropriate Instructions for Use or Operator's Manual.

PHOXILLUM and PRISMASOL Renal Replacement Solution Indications and Important Risk Information

Indications and Usage 
PRISMASOL and PHOXILLUM solutions are indicated in pediatric and adult patients for use as a replacement solution in Continuous Renal Replacement Therapy (CRRT) to replace plasma volume removed by ultrafiltration and to correct electrolyte and acid-base imbalances. They may also be used in case of drug poisoning when CRRT is used to remove dialyzable substances.

Warnings and Precautions 
Electrolyte and Volume Abnormalities
PHOXILLUM and PRISMASOL solutions can affect electrolytes and volume and may result in hyperkalemia or hyperphosphatemia. Monitor hemodynamic status and fluid inputs and outputs, potassium, phosphorous, calcium, other electrolytes and acid-base balance throughout the procedure. Abnormalities may be corrected by changing the formulation of replacement solution and/or dialysate, supplementation, or adjusting flow rates appropriately. PHOXILLUM replacement solutions contain hydrogen phosphate, a weak acid that may increase the risk of metabolic acidosis.

Blood Glucose Abnormalities
The use of PRISMASOL and PHOXILLUM replacement solutions can affect blood glucose levels resulting in hypo- or hyper-glycemia depending upon the dextrose content of the replacement solution. Monitor blood glucose levels regularly. Patients may require initiation of or modification of antidiabetic therapy or other corrective measures during treatment.

Please see PHOXILLUM and PRISMASOL Solutions full Prescribing Information.

MARS is indicated for the treatment of drug overdose and poisonings. The only requirement is that the drug or chemical be dialyzable (in unbound form) and bound by charcoal and/or ion exchange resins.

MARS is not indicated for the treatment of chronic liver disease conditions or as a bridge to liver transplant. Safety and efficacy has not been demonstrated for those indications in controlled, randomized clinical trials. The effectiveness of the MARS device in patients that are sedated could not be established in clinical studies and therefore cannot be predicted in sedated patients.